parkinson's disease retatrutide clinical trial research numbers remain "remarkably" consistent, annual report finds retatrutide parkinson clinical trial 💊

Over the past five years, this convergence has driven extraordinary optimism that GLP-1s might meaningfully diminish dementia risk and perhaps even alter disease progression trajectory to a greater extent than other common diabetes medications [3]

Average participants lost 24.2% of starting body weight, but individual results ranged from 15.8% to 31.4%

Collectively, the analysis crowned Tirzepatide as the most potent agent for glucose lowering and weight loss, with Semaglutide a consistent runner-up

Non-arteritic anterior ischemic optic neuropathy (NAION) is characterized by optic nerve ischemia leading to abrupt vision loss, yet its pathophysiology remains inadequately understood [96]

A phase 2 trial with Retatrutide also noted slight increase in heart rate (around 10bpm) after 24 weeks, but that this increased heart rate subsides over time